• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

In-utero exposure to tenofovir-emtricitabine not associated with higher risk of adverse birth outcomes

byShani ChibberandDayton McMillan
May 1, 2018
in Chronic Disease, Emergency, Infectious Disease, Obstetrics, Pediatrics, Public Health
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Pairwise comparisons of tenofovir-emtricitabine and ritonavir-boosted lopinavir (TDF-FTC-LPV/r), zidovudine-lamivudine and ritonavir-boosted lopinavir (ZDV-3TC-LPV/r), and tenofovir-emtricitabine and ritonavir-boosted atazanavir (TDF-FTC-ATV/r) HIV regimens among pregnant women with HIV showed all three regimens had comparable risks of preterm birth, low birth weight, and neonatal death.

2. There was a higher risk of preterm birth, low birth weight, and adverse birth events noted among women who initiated any of the regimens prior to conception.

Evidence Rating Level: 2 (Good)

Study Rundown: Perinatal transmission of human immunodeficiency virus (HIV) has been greatly reduced by the introduction of antiretroviral (ART) therapy. There are several variations in ART therapy, and studies continue to explore which regimen options work best for specific subpopulations of HIV-infected mothers. A notable previous study found a greater risk of for premature infant birth and death in pregnant HIV patients taking ZDZ-3TC-LPV/r. The current analysis used data from two large United States based perinatal cohorts to study the comparative outcomes of tenofovir-emtricitabine and ritonavir-boosted lopinavir (TDF-FTC-LPV/r) versus zidovudine-lamivudine and ritonavir-boosted lopinavir (ZDV-3TC-LPV/r) versus tenofovir-emtricitabine and ritonavir-boosted atazanavir (TDF-FTC-ATV/r) on incidences of premature birth, low birth weight, or neonatal death. No substantial differences in premature birth, low birthweight, or neonatal death were found when comparing the three regimens, TDF-FTC-LPV/r to ZDV-STC-LPV/r to TDF-FTC-ATV/r. There was however, a higher risk of preterm birth, low birth weight, and adverse outcomes noted among women who initiated TDF-FTC-LPV/r before conception compared to women that initiated the other drug regimens before conception.

Strengths of this analysis include its use of two broad comprehensive databases, however limitations included small cohort numbers for certain study parameters, which limited the study’s power and its ability to calculate statistically significant differences.

Click to read the study, published in NEJM

RELATED REPORTS

Anal cancer screening cost-effective for men who have sex with men with human immunodeficiency virus aged above 35 years

Early induction of labour reduces shoulder dystocia rates in large for gestational age fetuses

Atosiban does not improve neonatal outcomes in threatened preterm births between 30-34 weeks

Relevant Reading: Perinatal outcomes associated with maternal HIV infection: a systematic review and meta-analysis

In-Depth [retrospective cohort]: This retrospective cohort study compared data from the Surveillance Monitoring for ART Toxicities (SMARTT) study of the Pediatric HIV/AIDS Cohort Study (PHACS) and the P1025 study of the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) network. A total of 4646 mother-infant birth outcomes were included across both cohorts, corresponding to 3847 unique women. There were 128 mother-infant pairs (2.8%) that were exposed to TDF-FTC-LPV/r, 539 (11.6%) pairs exposed to TDF-FTC-ATV/r, and 954 (20.5%) pairs exposed to ZDV-3TC-LPV/r. Comparative analyses of TDF-FTC-LPV/r to ZDV-3TC-LPV/r showed that there was no increased risk of preterm birth (relative risk [RR], 0.90; 95% confidence interval [CI], 0.60 to 1.33), low birth weight (RR, 1.13; 95% CI, 0.78 to 1.64) or overall adverse events (RR, 0.92; 95% CI, 0.67 to 1.28) between groups. Similar findings showing no difference in any of the adverse outcomes were noted when TDF-FTC-LPV/r was compared to TDF-FTC-ATV/r. Subgroup analyses looking at women with their first singleton pregnancy or women who did not change ART regimens during therapy showed no significant change in RR when comparing ART regimens. Women who initiated any of the regimens prior to pregnancy had greater risks of preterm birth, very low birth weight, and severe adverse outcomes compared to women initiating therapy in their second or third trimester.

Image: PD

©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: antiretroviralhuman immunodeficiency virus (HIV)pregnancy
Previous Post

2 Minute Medicine Rewind April 30, 2018

Next Post

EXTEND-IA TNK: Tenecteplase is superior to alteplase as neoadjuvant treatment for mechanical thrombectomy

RelatedReports

Government-funded initiatives provide important supports to low-income HIV patients
Infectious Disease

Anal cancer screening cost-effective for men who have sex with men with human immunodeficiency virus aged above 35 years

June 16, 2025
Late gestation antidepressant use linked to postpartum hemorrhage
Obstetrics

Early induction of labour reduces shoulder dystocia rates in large for gestational age fetuses

June 11, 2025
Increased complications associated with emergent repeat cesarean
Obstetrics

Atosiban does not improve neonatal outcomes in threatened preterm births between 30-34 weeks

May 1, 2025
Combined immunotherapy may improve survival in metastatic pancreatic cancer
Infectious Disease

Safety of investigational vaccines against human immunodeficiency virus

April 29, 2025
Next Post
Treatment of subclinical hypothyroidism ineffective in older adults

EXTEND-IA TNK: Tenecteplase is superior to alteplase as neoadjuvant treatment for mechanical thrombectomy

HOSPITAL score predicts risk of 30-day potentially avoidable readmission to hospital

Hospital readmissions occurring within 7 days post-discharge may be more preventable than later readmissions

Screening insufficient for newborns exposed to hepatitis C virus

Screening insufficient for newborns exposed to hepatitis C virus

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Nerandomilast slows decline in FVC in idiopathic pulmonary fibrosis
  • Mazdutide significantly reduces weight in adults with overweight or obesity
  • Oral vancomycin may be effective for pouchitis in inflammatory bowel disease
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.